Common Equity: The sum of all common equity items.
Telomir Pharmaceuticals, Inc. (TELO) had Common Equity of $4.96M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-0.99M |
|
-- |
|
-- |
|
$1.04M |
|
$-1.04M |
|
$0.05M |
|
$-0.99M |
|
$-0.99M |
|
$-0.99M |
|
$-0.99M |
|
$-0.99M |
|
$-0.99M |
|
$-1.04M |
|
$-1.04M |
|
34.38M |
|
34.38M |
|
$-0.03 |
|
$-0.03 |
|
| Balance Sheet Financials | |
$5.79M |
|
-- |
|
-- |
|
$5.79M |
|
$0.83M |
|
-- |
|
-- |
|
$0.83M |
|
|
Common Equity |
$4.96M |
$4.96M |
|
$4.96M |
|
34.38M |
|
| Cash Flow Statement Financials | |
$-1.77M |
|
-- |
|
$0.05M |
|
$7.29M |
|
$5.56M |
|
$-1.73M |
|
$0.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.00 |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.77M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.97% |
|
-19.97% |
|
-17.12% |
|
-19.97% |
|
$0.14 |
|
$-0.05 |
|
$-0.05 |
|